Injection site reactions were reported in 14% of participants
Use of GLP-1 analogue drugs is associated with benefits but also health risks The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and obesity, may be associated with a wide range of health effects, both positive - such as a reduced risk of cardiometabolic disorders - and negative - an increased risk of gastrointestinal conditions or hypertension
doi: 10.1016/S0140-6736(15)00803-X 202 NewsomePNBuchholtzKCusiKLinderMOkanoueTRatziuVet al
Gong, Y., Yang, L., Tang, J., Zheng, J., Witman, N., Jakob, P., Tan, Y., Liu, M., Chen, Y., Wang, H., & Fu, W
The gut microbiome's role in GLP-1 regulation is an active area of research, with emerging evidence suggesting that microbial diversity and specific bacterial strains may influence incretin hormone secretion, but more human studies are needed to establish clinical significance